Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day...
-
Upload
kathlyn-baldwin -
Category
Documents
-
view
216 -
download
1
Transcript of Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day...
![Page 1: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/1.jpg)
Innovative Medicines InitiativeFinancial and IPR aspects
Magali Poinot Legal Manager
Info Day Bucharest, 10 December 2012
![Page 2: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/2.jpg)
Participation and Funding Rules
![Page 3: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/3.jpg)
Who can participate?
• Any entity carrying out work relevant to the IMI in a Member State or Associated Country
• Anyone else with the agreement of the IMI JUBUT
Not all participating entities are eligible for funding
• Stage 1 : at least two independent legal entities eligible for funding
• Stage 2: + at least 2 EFPIA companies
![Page 4: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/4.jpg)
Who is eligible for IMI funding?
• Academic institutions
• Non-profit research organizations
• Small & medium-size enterprises
• Non-profit patient organizations
• Non-profit public bodies and intergovernmental
organizations including specialized agencies
carrying out activities in a Member State or a country associated to FP7
![Page 5: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/5.jpg)
Which activities at which rate?
• Research activities• up to75% of total eligible costs
• Other activities -> management, training,
communication, …• up to 100% of total eligible costs
NEW! No impact for beneficiaries changing their status
![Page 6: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/6.jpg)
Which costs?
• Direct eligible costs -> personnel, consumables,
equipment,…• Personnel costs: either actual or average personnel costs if
aligned with usual accounting practices and applied in other
EU programmes
• SME Owners who do not receive a formal salary may use a
flat rate similar to the one used in the EU’s FP7 People
programme
![Page 7: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/7.jpg)
Which costs?
• Indirect eligible costs –> overheads• Flat-rate of 20% of direct eligible costs
• actual indirect costs
![Page 8: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/8.jpg)
Eligible vs. Ineligible costs
• Actual
• Incurred by the participant during the
project
• Determined according to usual
accounting and management principles
and practices
• Recorded in the accounts of the
participant
• Incurred for work carried out in a
Member State or associated country
• Incurred for the sole purpose of
achieving the project objectives related
to an activity accordingly described
• Identifiable indirect taxes including
value added tax
• Duties
• Interest owed
• Provisions for possible future losses or
charges
• Exchange losses, cost related to return
on capital
• Costs declared or incurred, or
reimbursed in respect of another Union
project
• Debt and debt service charges, excessive
or reckless expenditure
![Page 9: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/9.jpg)
EFPIA in-kind contribution
• Actual direct and indirect costs or average FTE
• Based on the usual management principles and
accounting practices
• Contribution from EFPIA affiliated entities as part of
EFPIA in-kind
For research costs incurred in Europe
unless expressly foreseen (see AMR 6th Call)
![Page 10: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/10.jpg)
Simplified accounting/reporting
• Yearly periodic financial reports: not need to be
certified by independent auditors, if either: • cost calculations is based on a certified accounting
methodologies within FP7
• the total amount of the participant’s report is <€375.000
• Yearly periodic reports: due either on July or
December, depending on the project’s starting date
![Page 11: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/11.jpg)
Intellectual Property Policy
![Page 12: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/12.jpg)
Guiding principles
Aligned with IMI objectives -> PPP, specific research
needs and challenges:•To achieve a broad participation
•To promote knowledge creation, disclosure and exploitation
•To achieve fair allocation of rights and reward innovation
•To provide flexibility for participants to establish the most
appropriate agreements serving the project objectives -> Project
Agreement
![Page 13: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/13.jpg)
• Contractual arrangement between all participants to set out their rights and obligations, especially governance, liability and IPR
• Shall comply with the IMI model Grant Agreement
• Mandatory before the signature of the grant agreement with the Executive Office
• To be adapted to the specific needs of each IMI project!
Project Agreement
![Page 14: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/14.jpg)
Start of End of the project the project implementation
Background Foreground
// Sideground // (generated during the Project but outside the Project Objectives
and not needed for implementation or Research Use) possible access rights
Background vs. Foreground
![Page 15: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/15.jpg)
Ownership: basic principles
• Background remains the exclusive property of each
participant
• Foreground are owned by the generator(s)
• Possibility to freely license, assign or otherwise dispose
of its ownership rights provided access rights to other
partners are respected
• Possible transfer of ownership
• Possible joint ownership
![Page 16: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/16.jpg)
Protection & Publications
• Common practices (not mandatory):• lies with the owner(s) in adequate and effective manner ->
relevant (national) legal provisions, project’s peculiarities,
legitimate interests
• if valuable Foreground left unprotected -> to be discussed within
the consortium
• Mandatory mention to IMI support & EFPIA in-kind
contribution in patent applications / publications (NEW!)
• Promotion of open access publications (NEW!)
![Page 17: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/17.jpg)
Access Rights: basic principles
• Granted on written request, unless otherwise agreed
• Non-exclusive basis approach
• No sub-licences, unless otherwise agreed
• Not affected by the termination of participation
• Guiding framework depending on the purpose:• Research Use -> further developments
• Exploitation -> commercialisation
![Page 18: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/18.jpg)
Access Rights: conditionsAccess rights granted by a Participant to/on Background
(necessary and identified)Foreground Sideground
Participants for completion of the Project
Royalty-free Royalty-free N.A.
Participants and affiliates for Research Use
Royalty-free ORFair & reasonable terms
for Background needed for using Foreground as determined in
Project Agreement
Royalty-free ORFair & reasonable termsas determined in Project
Agreement
N.A.
Third Parties for Research Use after the Project
Fair & reasonable termsfor Background needed for using
Foreground as determined in Project Agreement
Fair & reasonable termsas determined in Project
AgreementN.A.
Participants and affiliates or Third Parties for Direct Exploitation
To be negotiated To be negotiated N.A.
![Page 19: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/19.jpg)
More information
![Page 20: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/20.jpg)
Useful documents
• IMI model Grant Agreement (lastly revised on 30 April 2012)
• IMI Financial Guidelines (January 2012)
• IMI Reporting Templates and Guidelines (February 2012)
• IP Guidance Note (November 2010)
www.imi.europa.eu/content/documents
![Page 21: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/21.jpg)
Info material and publications
• Flyer and leaflet on IMI
• Fact sheets on IMI activities & projects
• Info and Slide set on IMI Calls
www.imi.europa.eu/content/info-material-and-
publication
![Page 22: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/22.jpg)
Find project partners
• Use the IMI Partner Search Tool http://
www.imi.europa.eu/content/partner-search
• Get in touch with your local IMI contact point:
www.imi.europa.eu/content/states-representatives-g
roups
• Talk to your FP7 Health National Contact Point (NCP)
![Page 23: Innovative Medicines Initiative Financial and IPR aspects Magali Poinot Legal Manager Info Day Bucharest, 10 December 2012.](https://reader030.fdocuments.net/reader030/viewer/2022032804/56649e535503460f94b49bf6/html5/thumbnails/23.jpg)